Horizon Therapeutics ticks higher as Amgen end date extended until December (update)
Mario Tama
Update 9am: Adds Amgen CEO comment on deal close timing. 
Horizon Therapeutics (NASDAQ:HZNP) ticked up 0.6% after the end date for its planned $28 billion sale to Amgen was extended until December.
The end date was extended to Dec. 12, according to an 8-K filing on Tuesday.
A week ago, Horizon Therapeutics (HZNP) announced that the Irish High Court had set Oct. 5 for a hearing on its planned $28 billion sale to Amgen (NASDAQ:AMGN).
Approval from the Irish High Court is the last remaining clearance the deal needs before it can close.
Amgen (AMGN) CEO Robert Bradway said he expects the Horizon (HZNP) deal to close by mid October, he commented Tuesday morning at the Morgan Stanley Global Healthcare conference.
More on Horizon Therapeutics

Seeking Alphaâs Quant Rating on Horizon Therapeutics
Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion?
Improved Outlook For Horizon Therapeutics And Amgen
Irish High Court hearing for Horizon's $28B sale to Amgen set for Oct. 5
Horizon Therapeutics gains afer FTC settles with Amgen over $28B deal (update)
Court hearing on FTC's challenge to Horizon/Amgen rescheduled until next week
Biggest stock movers today: Hawaiian Electric, RPT Realty, VinFast Auto and more